<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283374</url>
  </required_header>
  <id_info>
    <org_study_id>9804Z1-900</org_study_id>
    <nct_id>NCT00283374</nct_id>
  </id_info>
  <brief_title>Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome</brief_title>
  <official_title>A Prospective, Longitudinal Multicenter, Nontreatment, Exploratory Biomarker Study of Metabolic Syndrome in Subjects Undergoing Laparoscopic Roux-En-Y Gastric Bypass Bariatric Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its&#xD;
      definition is still evolving. Patients with this syndrome are at increased risk for&#xD;
      cardiovascular disease, and at increased risk of mortality from cardiovascular disease.&#xD;
&#xD;
      Metabolic syndrome is strongly associated with obesity, and more specifically with abdominal&#xD;
      obesity. Abdominal obesity, comprises two main components: visceral (VAT) and subcutaneous&#xD;
      (SAT) adipose tissue depots, with VAT reported as more metabolically active than SAT, and&#xD;
      thought to play a major role in the metabolic disturbances associated with obesity and&#xD;
      metabolic syndrome.&#xD;
&#xD;
      Non-alcoholic fatty liver disease (NAFLD) is fast becoming the most common liver disease and&#xD;
      is associated with obesity, insulin resistance and metabolic syndrome.&#xD;
&#xD;
      Bariatric surgery has yielded dramatic results including longitudinal loss of excess body&#xD;
      weight and either complete reversal or significant improvement of several features of&#xD;
      metabolic syndrome, NAFLD, and nonalcoholic steatohepatitis (NASH) in obese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Metabolic Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Roux-en-Y Gastric Bypass</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects must be approved by both insurance and site standard of care to undergo&#xD;
             the Roux-en-Y gastric bypass procedure&#xD;
&#xD;
          -  Male and Female Candidates for Roux-en-Y Bariatric Surgery&#xD;
&#xD;
          -  Must be diagnosed with Metabolic Syndrome; having abdominal obesity and at least 2&#xD;
             other features of the syndrome per IDF (International Diabetes Foundation)&#xD;
&#xD;
          -  Obese control group:Subjects should be obese and should not have any other features of&#xD;
             metabolic syndrome.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subjects with prior bariatric surgery&#xD;
&#xD;
          -  No other major surgery within the last 6 months&#xD;
&#xD;
          -  Diabetes on treatment with hypoglycemic medication in the previous 6 months&#xD;
&#xD;
        Other exclusions apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Italy, decresg@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Sweden, MedInfoNord@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-1050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aosta</city>
        <zip>11100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>116 91</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>182- 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>May 17, 2006</last_update_submitted>
  <last_update_submitted_qc>May 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2006</last_update_posted>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Bariatric Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

